Health Canada Approves Trikafta for CF Patients, Ages 12 and Up

Health Canada Approves Trikafta for CF Patients, Ages 12 and Up

297312

Health Canada Approves Trikafta for CF Patients, Ages 12 and Up

Health Canada has approved Trikafta  as a triple-combination therapy for people with cystic fibrosis (CF), ages 12 and up, who have at least one F508del mutation, the most common CF-causing mutation. This decision is expected to give about 1,100 people access for a first time to a therapy that directly addresses the underlying cause of their disease, according to Trikafta’s developer, Vertex Pharmaceuticals. A study drawing on Canadian data estimated that CF-related deaths across that country could drop…

You must be logged in to read/download the full post.